The University of Chicago Header Logo
Last Name


Search Results to Jason Luke

This is a "connection" page, showing the details of why an item matched the keywords from your search.


One or more keywords matched the following properties of Luke, Jason

overview Dr. Luke is Assistant Professor of Medicine within the Division of Biological Sciences, section of Hematology/Oncology. He is a clinical investigator with a research focus on drug development (emphasis in immunotherapy) and translational biomarker investigation. His clinical focus is in the management of patients with melanoma and advanced solid tumor malignancies.

One or more keywords matched the following items that are connected to Luke, Jason

Item TypeName
Concept Immunotherapy
Academic Article Chemotherapy in the management of advanced cutaneous malignant melanoma.
Academic Article Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
Academic Article Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?
Academic Article PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma.
Academic Article Have we won the race in the treatment of advanced melanoma-or are we just learning to walk?
Academic Article Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
Academic Article Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era.
Academic Article Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.
Academic Article Mechanistic and pharmacologic insights on immune checkpoint inhibitors.
Academic Article Targeted agents and immunotherapies: optimizing outcomes in melanoma.
Academic Article The Phoenix Rises: The Rebirth of Cancer Immunotherapy.
Academic Article Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy).
Academic Article The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
Academic Article Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
Academic Article Recent insights into the use of combination immunotherapy in solid tumors.
Academic Article T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.
Academic Article Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.
Academic Article Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.
Academic Article The Impact of the Fecal Microbiome on Cancer Immunotherapy.
Academic Article Facial Palsy Induced by Checkpoint Blockade: A Single Center Retrospective Study.
Academic Article Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).
Academic Article Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.
Academic Article The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development.
Academic Article Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
Academic Article Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy).
Academic Article Tumor-reprogrammed resident T cells resist radiation to control tumors.
Academic Article Secondary resistance to immunotherapy associated with ß-catenin pathway activation or PTEN loss in metastatic melanoma.
Academic Article BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma.
Academic Article Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes.
Academic Article Approaches to High-Risk Resected Stage II and III Melanoma.
Academic Article Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.
Academic Article Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma.
Academic Article Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response.
Academic Article Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST.
Academic Article Considering adjuvant therapy for stage II melanoma.
Academic Article Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).
Academic Article Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy.
Academic Article Radiation treatment planning study to investigate feasibility of delivering Immunotherapy in Combination with Ablative Radiosurgery to Ultra-High DoSes (ICARUS).
Academic Article Case Report: Single Dose Anti-PD1 in a Patient With Metastatic Melanoma and Cardiac Allograft.
Academic Article Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy).
Academic Article Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy.
Academic Article Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma.
Academic Article Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition.
Academic Article Stereotactic Body Radiation Therapy and Immunotherapy in Abdominal and Pelvic Lymph Node Metastases.
Academic Article Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas.
Academic Article A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma.
Academic Article Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy.
Academic Article The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.
Academic Article Optimal systemic therapy for high-risk resectable melanoma.

Search Criteria
  • Immunotherapy